Circassia's allergen immunotherapies to generate potential revenue of £1.3bn

SOUTHWARK, U.K. - June 4, 2015 - PRLog -- Circassia is working on four main treatments for allergies caused by house dust mites, grass, ragweed pollen and cat fur. The latter treatment, Cat-SPIRE, is due to report phase III clinical trial results in the first half of 2016. If successful, analysts forecast they could rake in annual sales of £1.3bn. The treatments were developed by researchers at Imperial College London and acquired by Circassia in 2006 when the firm was founded.
(Source: 'Cat allergy treatment could net billions for UK pharma Circassia', 26 Feb 2015, The Guardian)

Against this backdrop, we are delighted to announce that Circassia's Vice President R&D, Rod Hafner, will be presenting on Day 1 of SMi's 2nd annual Allergies conference on Challenges in the development of allergen immunotherapies.

Unique insight will be provided on the following areas:
• An introduction into the current situation in allergen immunotherapies
• Identification of key challenges and opportunities in the field
• Synthetic Peptide Immuno-Regulatory Epitopes: a new class of compounds

Additionally, Imperial College London's Professor of Respiratory Immunology, Clare Lloyd, will be leading a presentation titled Alternaria-derived serine protease: a novel pathway for asthma exacerbations mapped. Topics to be discussed include:
• Discussing the pathway involved in severe asthma exacerbations
• Providing a new target for therapeutics

SMi's 2nd annual Allergies conference, taking place on 8-9 July 2015 in London, will detail the latest cutting-edge developments in the field and the provide guidance on the direction allergy therapeutics is heading with case study driven presentations from innovators such as MedImmune, Circassia, Allergy Therapeutics, HAL Allergies and many more.

To view the full speaker line-up and complete conference programme, visit http://www.smi-online.co.uk/goto/2015allergies23.asp